Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares Global Tech ETF (IXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares Global Tech ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while iShares Global Tech ETF trades at $136.45. Which is the better fit depends on your goals.
| ACAD | IXN | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $149.74 |
52-Week Low | $20.06 | $92.92 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
IXN trades at $139.47, up 2.18% on the day, with a neutral technical signal overall. The ETF's technical indicators show mixed signals, with moving averages bearish and oscillators neutral. Recent news highlights its strong global tech exposure but notes high valuations and concentration risks. No recent financial statements or cash flow data are provided in the context for the current period.
The outlook for IXN is cautious due to stretched valuations and high expectations, with sentiment divided among analysts. Key risks include tech sector volatility and dependence on AI-driven growth. Investors should weigh the ETF's tech leadership against valuation concerns before making decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →
